Core Viewpoint - The company expects a revenue growth of approximately 110% to 120% in 2025, with an adjusted net loss not exceeding 240 million yuan, a reduction of over 50% compared to the previous year's loss of approximately 482 million yuan [1] Revenue Growth - The revenue increase is primarily attributed to the breakthrough in the commercialization of the core product, the Tumi laparoscopic surgical robot, particularly in overseas market expansion [1] - The company signed over 100 new orders in overseas markets throughout the year, with overseas sales revenue exceeding five times that of the previous year [1] - As of the announcement date, the total commercialized orders for Tumi globally exceeded 180 units, with the cumulative installed base surpassing 120 units [1] Loss Reduction - The narrowing of losses is mainly due to revenue growth and cost reduction measures, leading to a decrease in product costs and operating expenses [1] - The company anticipates that the net outflow of free cash flow in 2025 will narrow by over 80% compared to 2024, not exceeding 70 million yuan [1]